Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Artisan International Small-Mid Fund Q3 2025 Performance Review
08:05am, Wednesday, 26'th Nov 2025
Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
07:00am, Monday, 24'th Nov 2025
Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Globa
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
07:23am, Saturday, 22'nd Nov 2025
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Con
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:02pm, Thursday, 20'th Nov 2025
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants t
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
12:56pm, Wednesday, 19'th Nov 2025
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52
Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have pri
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:58pm, Tuesday, 18'th Nov 2025
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The in
Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In t
ABC Arbitrage SA Acquires New Position in Genmab A/S Sponsored ADR $GMAB
03:40am, Wednesday, 12'th Nov 2025
ABC Arbitrage SA bought a new position in Genmab A/S Sponsored ADR (NASDAQ: GMAB) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to ma
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend t
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript
06:46am, Saturday, 08'th Nov 2025
Genmab A/S (GMAB) Q3 2025 Earnings Call November 6, 2025 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd
03:40am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd decreased its holdings in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 9.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. T
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
12:58pm, Wednesday, 05'th Nov 2025
Media Release COPENHAGEN, Denmark; November 5, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will par
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
09:05am, Monday, 03'rd Nov 2025
Media Release COPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded
